<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860428</url>
  </required_header>
  <id_info>
    <org_study_id>04011994</org_study_id>
    <nct_id>NCT03860428</nct_id>
  </id_info>
  <brief_title>Early Treatment Versus Expectant Management of PDA in Preterm Infants</brief_title>
  <official_title>Randomized Non-inferiority Trial of Early Treatment Versus Expectant Management of Patent Ductus Arteriosus in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lviv National Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lviv National Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patent ductus arteriosus (PDA) in very preterm newborns is associated with severe neonatal&#xD;
      mor-bidity: intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD), necrotizing&#xD;
      en-terocolitis (NEC), retinopathy of prematurity (ROP). Existing methods of management PDA do&#xD;
      not reduce the incidence of these diseases. The efficacy of cyclooxygenase inhibitors (COX)&#xD;
      which are currently the standard of treatment in extreme preterm infants is about 70-80%. COX&#xD;
      inhibitors have significant side effects. On the other hand, surgical ligation of the ductus&#xD;
      arteriosus is associated with deterioration due to cardio-pulmonary problems and long-term&#xD;
      complications. Paracetamol has been proposed for treatment of hemodynamically significant PDA&#xD;
      because it has a different mecha-nism of action compared with COX inhibitors and a better&#xD;
      safety profile.&#xD;
&#xD;
      Recently, expectant approach has becoming more popular, although there is not enough evidence&#xD;
      to support it.&#xD;
&#xD;
      The objective of this study is to investigate whether in preterm infants, born at a GA less&#xD;
      than 32 weeks, with a PDA (diameter &gt; 1.5 mm) at a postnatal age of &lt; 72 h, an expectant&#xD;
      management is non-inferior to early treatment with regard to the composite of mortality&#xD;
      and/or severe morbidity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2019</start_date>
  <completion_date type="Actual">July 20, 2021</completion_date>
  <primary_completion_date type="Actual">July 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of bronchopulmonary dysplasia (BPD) or mortality at 36 weeks postmenstrual age (PMA)</measure>
    <time_frame>36 weeks PMA</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PDA re-opening rate</measure>
    <time_frame>Day 1 up to 3 month</time_frame>
    <description>PDA re-opening after echocardiographically documented closure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure to close the duct within a week after the first and second course of pharmacological treatment</measure>
    <time_frame>Participants will be evaluated at the end of first and second course, at an expected avarage of 10 days of life</time_frame>
    <description>The rate of failures closing the duct after the first and second course of the specific therapy with rectal ibuprofen and intravenous paracetamol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need for surgical ductus closure</measure>
    <time_frame>Day 1 up to 3 month</time_frame>
    <description>The rate of surgical ligation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of any ventilation assist</measure>
    <time_frame>Day 1 up to 3 month</time_frame>
    <description>The ventilation assist time period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total days of oxygen supplementation</measure>
    <time_frame>Day 1 up to 3 month</time_frame>
    <description>Days on supplement oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age of administration of full volume of enteral nutrition</measure>
    <time_frame>Day 1 up to 3 month</time_frame>
    <description>Day till the infant reaches 120 kcal/kg/d</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of oliguria</measure>
    <time_frame>In the first 14 days of life</time_frame>
    <description>Rate of oliguria defined as a reduction on urine output less than 1ml/Kg/h,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypotension</measure>
    <time_frame>Day 1 up to 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of BPD</measure>
    <time_frame>36 weeks PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>36 weeks PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe intraventricular hemorrhage</measure>
    <time_frame>28-days since birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of necrotizing enterocolitis (Bell stage ≥ IIa)</measure>
    <time_frame>36 weeks PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of periventricular leukomalacia</measure>
    <time_frame>36 weeks PMA</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <arm_group>
    <arm_group_label>Rectal ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early treatment of PDA that starts within the first 3 days of life using rectal ibuprofen q24h for 3 days, dosages: 20 mg/kg + 10 mg/kg + 10 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early treatment of PDA that starts within the first 3 days of life using intravenous paraceta-mol 15 mg/kg q6h for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expectant Treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Expectant PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA unless defi-nitely needed based of the predefined infant's condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>In the medical treatment arm the in-tention is to close the ductus arteriosus.</description>
    <arm_group_label>Rectal ibuprofen</arm_group_label>
    <other_name>Cyclooxygenase Inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>In the medical treatment arm the in-tention is to close the ductus arteriosus.</description>
    <arm_group_label>Intravenous paracetamol</arm_group_label>
    <other_name>Infulgan, Acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Expectant Management</intervention_name>
    <description>Expectative PDA management is character-ized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.</description>
    <arm_group_label>Expectant Treatment</arm_group_label>
    <other_name>Conservative management</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age &lt; 32 weeks&#xD;
&#xD;
          -  Birthweight &lt;1500 g&#xD;
&#xD;
          -  Age less than 72 hours&#xD;
&#xD;
          -  PDA diameter &gt; 1.5 mm&#xD;
&#xD;
          -  Signed informed consent obtained from both parents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Birthweight ≥ 1500 g and/or gestation age ≥ 32 weeks&#xD;
&#xD;
          -  Lack of informed consent of the parents&#xD;
&#xD;
          -  Congenital heart defect, other than PDA and/or patent foramen ovale (PFO)&#xD;
&#xD;
          -  The presence of a clinically apparent hemorrhagic syndrome&#xD;
&#xD;
          -  Any intraventricular hemorrhage (IVH) in the first 48 hours or IVH grade 3-4&#xD;
&#xD;
          -  A platelet count of &lt; 50,000/mm3&#xD;
&#xD;
          -  A serum creatinine concentration of &gt; 110 μmol/L&#xD;
&#xD;
          -  Oliguria &lt;1 ml/kg/h&#xD;
&#xD;
          -  Suspected/apparent NEC&#xD;
&#xD;
          -  Suspected/apparent lung hypoplasia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmytro Dobryanskyy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>L'viv National Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lviv National Medical University</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 16, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lviv National Medical University</investigator_affiliation>
    <investigator_full_name>Dmytro Dobryanskyy</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>PDA</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Paracetamol</keyword>
  <keyword>Expectant management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Cyclooxygenase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

